IBRX

ImmunityBio's stock (IBRX) has shown significant upward momentum in the past six months, increasing by 42.99% and by 310.28% over the year, with the share price reaching $10.38 on October 5, 2026. This growth is primarily driven by strong net product revenue from ANKTIVA, which saw Q1 2026 revenue of $44.2 million (168% year-over-year increase) and Q2 2026 revenue of $50.7 million (92% year-over-year increase), marking eight consecutive quarters of sequential growth. Global regulatory approvals and pipeline advancements, such as the UAE's broad marketing authorization for ANKTIVA and the FDA's acceptance of a supplemental Biologics License Application for papillary NMIBC, have positively influenced investor sentiment. Additionally, the company secured $75 million in non-dilutive financing in March 2026, increasing its total committed capital to $375 million, supporting global expansion and pipeline development. Corporate presentations and positive clinical sentiment for its oncology pipeline have also attracted investor interest, though there remains a tension between speculative growth enthusiasm and underlying fundamental risks like persistent net losses and cash burn, alongside routine insider share sales.